898.2101  19.72 (2.24%)		06-17 09:56
Open: 890.29 High: 898.82 Volume: 60,716		Pre. Close: 878.49 Low: 883.76 Market Cap: 55,584(M)

Short term
Mid term
Targets	6-month :	1065.06	1-year :	1244
Resists	First :	911.87	Second :	1065.06
Pivot price	862.07
Supports	First :	827.66	Second :	775.61
MAs	MA(5) :	888.62	MA(20) :	849.35
	MA(100) :	796.35	MA(250) :	770.55
MACD	MACD :	23.3	Signal :	20.6
%K %D	K(14,3) :	76.1	D(3) :	80
RSI	RSI(14): 61.1
52-week	High :	934.61	Low :	510.05

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ARGX ] has closed below upper band by 28.7%. Bollinger Bands are 21.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	886.04 - 893.26	893.26 - 898.11
Low:	854.78 - 862.79	862.79 - 868.17
Close:	867.97 - 880.42	880.42 - 888.77

argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejection. Also noted in connection with its lead product efforts is ENHANZE SC. The company's extensive development pipeline features several other promising candidates. Empasiprubart is in development for multifocal motor neuropathy, delayed graft function, and dermatomyositis. ARGX-119 is being investigated for congenital myasthenic syndrome and amyotrophic lateral sclerosis. Further pipeline assets include ARGX-213, which targets FcRn; ARGX-121 and ARGX-220, both designed to modulate the immune system; ARGX-109, which targets IL-6; and ARGX-118, developed for inflammatory indications. argenx is also advancing cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. The company’s portfolio encompasses several proprietary products and brands, such as VYVGART, VYVGART HYTRULO, VYVDURA, ARGENX, ABDEG, NHANCE, SIMPLE ANTIBODY, and ARGENXMEDHUB. Strategic collaborations are integral to argenx's business model. It maintains partnerships with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S, alongside numerous collaboration and license agreements with entities including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. A specific collaboration with Genmab A/S focuses on the discovery, development, and commercialization of novel therapeutic antibodies for immunology and oncology applications. Additionally, argenx has a strategic collaboration with IQVIA Holdings Inc. for the provision of safety systems and related services.

Wed, 17 Jun 2026
ARGENX : Goldman Sachs reiterates its Buy rating - marketscreener.com

Wed, 17 Jun 2026
ARGX shares gain nearly 9% in a month: Here's what you need to know - MSN

Sat, 13 Jun 2026
Argenx SE (ARGX): A Promising Growth Stock to Buy on the Autoimmune Rheumatic Disease Opportunity - Insider Monkey

Sat, 13 Jun 2026
How Argenx Se (ARGX) Affects Rotational Strategy Timing - Stock Traders Daily

Sat, 13 Jun 2026
Argenx (ENXTBR:ARGX) Stock Valuation After Expanded FDA Approval For Vyvgart And Pipeline Progress - simplywall.st

Wed, 10 Jun 2026
Assessing argenx (ENXTBR:ARGX) Valuation After Strong Recent Share Price Momentum - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	62 (M)
Shares Float	1,550 (M)
Held by Insiders	0 (%)
Held by Institutions	47.5 (%)
Shares Short	1,810 (K)
Shares Short P.Month	2,080 (K)

EPS	22.51
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	4.73
Profit Margin	31.3 %
Operating Margin	30 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	62.5 %
Gross Profit (p.s.)	44.38
Sales Per Share	76.21
EBITDA (p.s.)	21.22
Qtrly Earnings Growth	114 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	39.44
PEG Ratio	1.5
Price to Book value	187.73
Price to Sales	11.65
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.